ArticleArquivos de gastroenterologia2026
LIMITED DIAGNOSTIC ACCURACY OF FIB-4 FOR DETECTING SIGNIFICANT LIVER FIBROSIS IN CHRONIC HEPATITIS B: A CROSS-SECTIONAL STUDY.
Article in Arquivos de gastroenterologia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLiver disease linked to the hepatitis B virus (HBV) is a serious public threat worldwide and in Egypt. The incidence of HBV infection in Egypt is about 1.4%. Accurate liver fibrosis assessments are crucial in the evaluation and follow-up of HBV patients, but traditional biopsies have limitations, prompting the use of non-invasive methods like the vibration controlled transient elastography (VCTE), which may not be available in limited-resource treatment centers.
objectiveThis study aimed to assess the diagnostic accuracy of Fibrosis-4 (FIB-4) and Aminotransferase to Platelet Ratio Index (APRI) compared to VCTE in detecting significant liver fibrosis in adult chronic HBV patients, potentially offering a more accessible and less costly approach to disease management. Methods - In this cross-sectional study, 247 subjects with chronic HBV from Alexandria University Viral Hepatitis Treatment Unit were included. Data collected included demographic details, HBV viral load, liver function tests, Complete Blood Count (CBC), international normalized ratio (INR), prothrombin time, albumin, total and direct bilirubin, APRI score, FIB-4 score, imaging, and VCTE data. IBM SPSS software was used for statistical analysis, with qualitative and quantitative data described appropriately. Logistic regression and receiver operating characteristic curve (ROC) curves were used to identify significant predictors of advanced fibrosis and assess diagnostic performance.
resultsBased on VCTE results, 247 chronic hepatitis B patients were classified into two groups: 140 with no or mild fibrosis (F0/1) and 107 with significant fibrosis (F2-F4). Significant differences were found in hemoglobin, albumin, and INR levels between the groups. The FIB-4 and APRI scores were significantly higher in the significant fibrosis group, with median FIB-4 scores of 1.26 vs 0.79 and median APRI scores of 0.40 vs 0.27. The FIB-4 index remained a significant predictor of significant fibrosis in multivariate analysis, with an odds ratio of 1.558. At a cut-off value of >0.88, the FIB-4 score achieved a sensitivity of 65.42% and a specificity of 60.0% in differentiating patients with and without significant fibrosis.
conclusionAlthough the use of FIB-4 score is potentially useful in resource-limited settings, a significant number of misclassifications can occur due to its moderate sensitivity and specificity which necessitate further incorporation of additional diagnostic methods to ensure the accurate staging of liver fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.